TuHURA Biosciences, Inc./NV (HURA) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
10500 UNIVERSITY CENTER DR. TAMPA, FL 33612 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q1 | 6/30/2024 Q4 | 3/31/2024 Q3 | 12/31/2023 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 6,219,831 | 12,657,178 | 3,020,000 | 4,909,000 | 6,351,000 | 658,000 | |||
| Cash and cash equivalent | 6,219,831 | 12,657,178 | 3,020,000 | 4,909,000 | 6,351,000 | 658,000 | |||
| Prepaid expense | 258,000 | 414,000 | 208,000 | 311,000 | |||||
| Other current assets | 1,002,671 | 958,708 | |||||||
| Other undisclosed current assets | 7,102,878 | 5,994,503 | 205,000 | 205,000 | 196,000 | 217,000 | |||
| Total current assets: | 14,325,380 | 19,610,389 | 3,483,000 | 5,528,000 | 6,755,000 | 1,186,000 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 161,317 | 199,160 | |||||||
| Property, plant and equipment | 151,980 | 123,366 | 657,000 | 674,000 | 691,000 | 699,000 | |||
| Intangible assets, net (including goodwill) | |||||||||
| Goodwill | |||||||||
| Other noncurrent assets | 33,769 | ||||||||
| Other undisclosed noncurrent assets | |||||||||
| Total noncurrent assets: | 313,297 | 356,295 | 657,000 | 674,000 | 691,000 | 699,000 | |||
| TOTAL ASSETS: | 14,638,677 | 19,966,684 | 4,140,000 | 6,202,000 | 7,446,000 | 1,885,000 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 4,617,620 | 5,170,166 | 2,207,000 | 2,207,000 | 1,243,000 | 1,722,000 | |||
| Accounts payable | 3,084,059 | 3,152,816 | 1,871,000 | ||||||
| Accrued liabilities | 1,452,062 | 1,161,650 | 336,000 | ||||||
| Other undisclosed accounts payable and accrued liabilities | 81,499 | 855,700 | 2,207,000 | 1,243,000 | 1,722,000 | ||||
| Debt | |||||||||
| Other liabilities | 52,000 | ||||||||
| Other undisclosed current liabilities | 164,594 | 159,844 | 50,000 | 98,000 | 148,000 | ||||
| Total current liabilities: | 4,782,214 | 5,330,010 | 2,257,000 | 2,259,000 | 1,341,000 | 1,870,000 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 42,698 | ||||||||
| Operating lease, liability | 42,698 | ||||||||
| Other undisclosed noncurrent liabilities | 188,000 | 186,000 | 183,000 | 179,000 | |||||
| Total noncurrent liabilities: | 42,698 | 188,000 | 186,000 | 183,000 | 179,000 | ||||
| Total liabilities: | 4,782,214 | 5,372,708 | 2,445,000 | 2,445,000 | 1,524,000 | 2,049,000 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 9,856,463 | 14,593,976 | 1,695,000 | 3,757,000 | 5,922,000 | (164,000) | |||
| Common stock | 43,680 | 42,324 | 2,000 | 55,000 | 55,000 | 10,000 | |||
| Additional paid in capital | 130,383,186 | 125,397,691 | 163,445,000 | 153,305,000 | 153,144,000 | 145,090,000 | |||
| Accumulated other comprehensive income | 21,000 | 21,000 | 21,000 | 21,000 | |||||
| Accumulated deficit | (117,791,029) | (111,124,569) | (162,052,000) | (159,876,000) | (157,550,000) | (155,537,000) | |||
| Stockholders' equity note, subscriptions receivable | (103,000) | ||||||||
| Other undisclosed equity, attributable to parent | (2,779,374) | 278,530 | 279,000 | 10,252,000 | 10,252,000 | 10,355,000 | |||
| Total equity: | 9,856,463 | 14,593,976 | 1,695,000 | 3,757,000 | 5,922,000 | (164,000) | |||
| TOTAL LIABILITIES AND EQUITY: | 14,638,677 | 19,966,684 | 4,140,000 | 6,202,000 | 7,446,000 | 1,885,000 | |||
Income Statement (P&L) (USD)Annual | Quarterly
| 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q1 | 6/30/2024 Q4 | 3/31/2024 Q3 | 12/31/2023 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (7,017,023) | (11,583,492) | (2,209,000) | (2,385,000) | (2,085,000) | (1,019,000) | ||
| Other operating income, net | 139,000 | |||||||
| Operating loss: | (7,017,023) | (11,583,492) | (2,209,000) | (2,246,000) | (2,085,000) | (1,019,000) | ||
| Nonoperating income (expense) | 352,652 | (4,102,814) | 48,000 | 61,000 | 74,000 | (4,000) | ||
| Loss, foreign currency transaction, before tax | (1,000) | (6,000) | ||||||
| Other nonoperating income | 352,652 | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (6,664,371) | (15,686,306) | (2,161,000) | (2,185,000) | (2,011,000) | (1,023,000) | ||
| Other undisclosed income from continuing operations before income taxes | 43,382,306 | |||||||
| Income (loss) from continuing operations before income taxes: | (6,664,371) | 27,696,000 | (2,161,000) | (2,185,000) | (2,011,000) | (1,023,000) | ||
| Other undisclosed loss from continuing operations | (3,768) | |||||||
| Income (loss) from continuing operations: | (6,664,371) | 27,692,232 | (2,161,000) | (2,185,000) | (2,011,000) | (1,023,000) | ||
| Other undisclosed net loss | (43,378,538) | (139,000) | ||||||
| Net loss attributable to parent: | (6,664,371) | (15,686,306) | (2,161,000) | (2,324,000) | (2,011,000) | (1,023,000) | ||
| Preferred stock dividends and other adjustments | (13,000) | |||||||
| Other undisclosed net loss available to common stockholders, basic | (2,089) | (788,266) | (2,000) | (2,000) | (2,000) | (2,000) | ||
| Net loss available to common stockholders, diluted: | (6,666,460) | (16,474,572) | (2,176,000) | (2,326,000) | (2,013,000) | (1,025,000) | ||
Comprehensive Income (USD)Annual | Quarterly
| 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q1 | 6/30/2024 Q4 | 3/31/2024 Q3 | 12/31/2023 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (6,664,371) | (15,686,306) | (2,161,000) | (2,324,000) | (2,011,000) | (1,023,000) | ||
| Comprehensive loss, net of tax, attributable to parent: | (6,664,371) | (15,686,306) | (2,161,000) | (2,324,000) | (2,011,000) | (1,023,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.